MedCost Clear Cost calculator

Drugs / Biktarvy

Biktarvy cost

bictegravir, emtricitabine and tenofovir alafenamide · Gilead. Every official price for Biktarvy, side by side, with who pays it.

Short answer

We found no list price published by Gilead. Pharmacies paid an average of $136.63–$136.75 per tablet (NADAC, Oct 21, 2026). In 2024, Medicare Part D spent $3.5 billion on Biktarvy, an average of $4,110.58 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.1523

Source: CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026

Biktarvy: the official numbers, by situation

PriceAmountWhose price, and who it applies toDate
List price Not published We found no list price published by Gilead. —
Pharmacy cost (NADAC)
per tablet; a month depends on your dose
$136.63–$136.751 What pharmacies pay on average (CMS survey). Not a patient price. Oct 21, 2026

None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.

FDA approval

Every official price

PriceAmountWhat it isDate
Maker's list price (WAC) Not published We found no current list price on Gilead's own pages, so we do not show one. —
Pharmacy acquisition cost (NADAC)
Biktarvy 30-120-15 mg tablet
$136.631 Per tablet. The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Biktarvy 50-200-25 mg tablet
$136.751 Per tablet. The national average price pharmacies pay to buy it. Oct 21, 2026

These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below.

What Medicare spent on Biktarvy in 2024

CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,6 and it does not reflect manufacturers' rebates.7

Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).

Product (as CMS lists it)Total spendingFillsPeoplePer fillPer person
Biktarvy $3.5 billion5 840,772 92,246 $4,110.588 $37,465.709

These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.

Medicare Part D spending on Biktarvy, 2020–2024

CMS Medicare Part D Spending by Drug, "Biktarvy" (all makers), gross cost before rebates, checked Nov 15, 2026.

YearTotal spendingPrescription fillsPeoplePer fill
2020$1.8 billion14500,40555,805$3,548.82
2021$2.2 billion14594,19766,319$3,699.56
2022$2.7 billion14686,16175,791$3,940.16
2023$3.2 billion14756,48683,843$4,166.97
2024$3.5 billion14840,77292,246$4,110.58
Per fill = total spending ÷ fills (matches CMS's own average). Totals for everyone in Part D who used it, not a price for one person.

Biktarvy cost with Medicare

With commercial insurance or no insurance

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (14)
  1. “Out-of-pocket limit Yearly $2,100 (in 2026).”
    Medicare.gov: Medicare costs · as of Oct 23, 2026
  2. “Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
  3. “NDA210251 ORIG-1 approved 20180207”
  4. “Biktarvy: Tot_Spndng_2024 3456061331.1, Tot_Clms_2024 840772, Tot_Benes_2024 92246”
  5. “Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
  6. “The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
  7. “Part D drug spending divided by the number of prescription fills.”
  8. “Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
  9. “Biktarvy Human immunodeficiency virus type 1 infection $3,904,486,000 101,000”
  10. “On January 27, 2026, CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations (initial price applicability year 2028)”
  11. “November 30, 2026 — Deadline for CMS to publish any agreed-upon MFPs resulting from the third cycle of negotiations and renegotiation.”
  12. “January 1, 2028 — Any agreed-upon MFPs negotiated for selected drugs from the third cycle of negotiations and drugs selected for renegotiation become effective.”
  13. “Biktarvy | Bictegrav/Emtricit/Tenofov Ala | Overall”

Did this page answer your question?